Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy
Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. We enrolled 25 patients HOCM who underwent PESA. The...
Saved in:
| Published in | BMC cardiovascular disorders Vol. 25; no. 1; pp. 564 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
02.08.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up.
We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure.
The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up.
PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. |
|---|---|
| AbstractList | ObjectivePercutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up.MethodsWe enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25–47.5 months), with transthoracic echocardiography performed 22 months (8–29 months) after the procedure.ResultsThe mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3–6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up.ConclusionsPESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure. The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up. PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. Abstract Objective Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. Methods We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25–47.5 months), with transthoracic echocardiography performed 22 months (8–29 months) after the procedure. Results The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3–6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up. Conclusions PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up.OBJECTIVEPercutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up.We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure.METHODSWe enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure.The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up.RESULTSThe mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up.PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM.CONCLUSIONSPESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. Objective Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. Methods We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure. Results The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up. Conclusions PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. Keywords: Hypertrophic obstructive cardiomyopathy, Septal radiofrequency ablation, Heart function, Cardiovascular magnetic resonance imaging Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. We enrolled 25 patients HOCM who underwent PESA. The combination of a three-dimensional electrophysiological mapping system and intracardiac echocardiography (ICE) was employed to guide PESA. The patients were followed for 37 months (25-47.5 months), with transthoracic echocardiography performed 22 months (8-29 months) after the procedure. The mean age of patients was 55.3 ± 13.5 years (range: 23 to 79), and 11 (44%) of them were female. PESA led to a significant reduction in the left ventricular outflow tract gradient (LVOTG) from 79.0 ± 37.6 mmHg to 55.6 ± 34.8 mmHg (p = 0.002), as well as syncope episodes (60% vs. 19%, p = 0.0039) in patients with HOCM. The New York Heart Association (NYHA) functional class of the patients was improved from 2.14 ± 0.57 to 1.76 ± 0.54 (p = 0.002). In 10 patients undergoing cardiovascular magnetic resonance imaging (CMRI) both before PESA and at a follow-up of 3-6 months, the maximum left ventricular outflow tract velocity was ameliorated from 232.6 ± 56.8 m/s to 159.4 ± 46.9 m/s (p = 0.024). Besides, the minimum systolic diameter of left ventricular outflow tract was increased from 3.84 ± 2.6 mm to 6.3 ± 2.3 mm (p = 0.0006). There were no instances of cardiac tamponade, lethal arrhythmia, or death. Four patients underwent surgical septal myectomy during the follow-up. PESA could attenuate LVOT obstruction and improve heart function in patients with HOCM during a long-term follow-up. PESA may be an effective and safe treatment for HOCM. |
| ArticleNumber | 564 |
| Audience | Academic |
| Author | Li, Jiaju Guo, Xiaogang Yao, Yan Sun, Qi Cheng, Yunjiu Tian, Aiju Chen, Xuhua Zhang, Tianjing Tang, Min Chen, Keping Jia, Yuhe Liu, Jun |
| Author_xml | – sequence: 1 givenname: Aiju surname: Tian fullname: Tian, Aiju – sequence: 2 givenname: Yunjiu surname: Cheng fullname: Cheng, Yunjiu – sequence: 3 givenname: Yuhe surname: Jia fullname: Jia, Yuhe – sequence: 4 givenname: Tianjing surname: Zhang fullname: Zhang, Tianjing – sequence: 5 givenname: Jiaju surname: Li fullname: Li, Jiaju – sequence: 6 givenname: Xuhua surname: Chen fullname: Chen, Xuhua – sequence: 7 givenname: Jun surname: Liu fullname: Liu, Jun – sequence: 8 givenname: Xiaogang surname: Guo fullname: Guo, Xiaogang – sequence: 9 givenname: Qi surname: Sun fullname: Sun, Qi – sequence: 10 givenname: Min surname: Tang fullname: Tang, Min – sequence: 11 givenname: Keping surname: Chen fullname: Chen, Keping – sequence: 12 givenname: Yan surname: Yao fullname: Yao, Yan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40753187$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktv1DAUhSNURB_wB1igSGzYpPgRx_YKVRXQSpVgAWvLdq5nPMrYwU6K5t_jmZS2g5AX17r-fOxzdc6rkxADVNVbjC4xFt3HjIngpEGENYghRBr8ojrDLccNIR0-ebY_rc5z3iCEuUDyVXXaIs4oFvysGr9DsvOkA8Q51xD6aHXqvR7qDONUStK9jy7BrxmC3dXaDHryMdQ-1GPZQZhy_dtP63q9GyFNKY5rb-to8pRmO_l7qA-CcbuLhV_vXlcvnR4yvHmoF9XPL59_XN80d9--3l5f3TW2pQQ3wlKmLSdW6FYS4yih2BlwmoHsneaMAQiKJJfG0l66rmW9AdS1miMtJKcX1e2i20e9UWPyW512KmqvDo2YVkqnydsBFCIdMS2TRnSmdUZKiQVg0wlpqBDYFa1Pi9Y4my30tphOejgSPT4Jfq1W8V7h8mvOOCoKHx4UUiyTzJPa-mxhGJbBq2KPyY5yKgr6_h90E-cUyqz2VCclEbh7ola6OPDBxfKw3YuqK8GKI4QJLtTlf6iyeth6W9LkfOkfXXj33Omjxb-BKQBZAJtizgncI4KR2qdSLaksQ2XqkEqF6R9tQtWd |
| Cites_doi | 10.1016/j.jacc.2010.07.055 10.3389/fcvm.2021.743044 10.1016/j.cpcardiol.2022.101552 10.1016/j.amjcard.2022.06.017 10.1002/ehf2.14272 10.1016/j.jacc.2024.11.030 10.1016/j.jacc.2018.07.080 10.1016/j.jacc.2020.08.044 10.1016/j.jacc.2011.09.020 10.1016/j.amjcard.2003.09.034 10.1016/j.pcad.2023.08.003 10.1161/CIRCULATIONAHA.104.507723 10.21037/atm-21-2783 10.1016/j.ihj.2016.02.007 10.33678/cor.2021.124 10.1093/eurheartj/ehae710 10.1093/europace/euv302 10.1016/j.jacc.2009.05.006 10.1016/j.jchf.2015.06.011 10.1002/clc.23341 10.1016/j.hrthm.2016.04.018 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12872-025-05002-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2261 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_0262b459b86b4fb99918e1b689b3881f PMC12317570 A850260121 40753187 10_1186_s12872_025_05002_1 |
| Genre | Journal Article |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: The Chinese Academy of Medical Sciences Clinical and Translational Medical Research Fund grantid: 2020-I2M-C&T-B-051 – fundername: Horizontal Research Projects grantid: T2016-ZX015 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ECGQY EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PUEGO 3V. 7QP 7XB 8FK AZQEC DWQXO K9. M48 PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c4321-8c35ac72c8a492bf3231fbefa5e9dfa755ee830979bc3d9f645dbe064a70a8973 |
| IEDL.DBID | 7X7 |
| ISSN | 1471-2261 |
| IngestDate | Wed Aug 27 01:24:25 EDT 2025 Thu Aug 21 18:32:29 EDT 2025 Sun Aug 03 23:52:59 EDT 2025 Wed Aug 06 19:21:55 EDT 2025 Wed Aug 27 16:52:38 EDT 2025 Tue Aug 05 03:51:27 EDT 2025 Thu Aug 07 06:28:35 EDT 2025 Thu Aug 07 05:44:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cardiovascular magnetic resonance imaging Heart function Septal radiofrequency ablation Hypertrophic obstructive cardiomyopathy |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4321-8c35ac72c8a492bf3231fbefa5e9dfa755ee830979bc3d9f645dbe064a70a8973 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3236992816?pq-origsite=%requestingapplication% |
| PMID | 40753187 |
| PQID | 3236992816 |
| PQPubID | 44077 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0262b459b86b4fb99918e1b689b3881f pubmedcentral_primary_oai_pubmedcentral_nih_gov_12317570 proquest_miscellaneous_3235963738 proquest_journals_3236992816 gale_infotracmisc_A850260121 gale_infotracacademiconefile_A850260121 pubmed_primary_40753187 crossref_primary_10_1186_s12872_025_05002_1 |
| PublicationCentury | 2000 |
| PublicationDate | 20250802 |
| PublicationDateYYYYMMDD | 2025-08-02 |
| PublicationDate_xml | – month: 8 year: 2025 text: 20250802 day: 2 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cardiovascular disorders |
| PublicationTitleAlternate | BMC Cardiovasc Disord |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | T Jiang (5002_CR26) 2022; 9 P Fitzgerald (5002_CR28) 2018; 52 K Doležalová (5002_CR22) 2022; 64 AB Shelke (5002_CR17) 2016; 68 A Achim (5002_CR9) 2023; 10 5002_CR15 E Braunwald (5002_CR2) 2024; 45 BA Maron (5002_CR4) 2022; 179 K Doležalová (5002_CR12) 2023; 65 K Crossen (5002_CR18) 2016; 13 H Yang (5002_CR7) 2020; 43 SR Ommen (5002_CR11) 2020; 76 N Mehra (5002_CR6) 2023; 80 L Kong (5002_CR16) 2021; 9 JX Qin (5002_CR29) 2004; 93 5002_CR1 L Liu (5002_CR25) 2018; 72 M Liebregts (5002_CR27) 2015; 3 N Sreeram (5002_CR21) 2011; 58 XY Guo (5002_CR13) 2022; 102 RM Cooper (5002_CR19) 2015; 18 C Rickers (5002_CR24) 2005; 112 SA Sebastian (5002_CR8) 2023; 48 T Lawrenz (5002_CR20) 2011; 57 Z Cheng (5002_CR5) 2021; 8 Y Jia (5002_CR10) 2021; 19 MS Maron (5002_CR23) 2009; 54 IK Gartzonikas (5002_CR3) 2023; 70 BP Valdigem (5002_CR14) 2022; 118 |
| References_xml | – volume: 57 start-page: 572 issue: 5 year: 2011 ident: 5002_CR20 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.07.055 – ident: 5002_CR15 doi: 10.3389/fcvm.2021.743044 – volume: 48 start-page: 101552 issue: 4 year: 2023 ident: 5002_CR8 publication-title: CURR PROB CARDIOLOGY doi: 10.1016/j.cpcardiol.2022.101552 – volume: 19 start-page: 381 issue: 04 year: 2021 ident: 5002_CR10 publication-title: Chin J Cardiovasc Res – volume: 65 start-page: 146 issue: 1 year: 2023 ident: 5002_CR12 publication-title: Cor Vasa – volume: 179 start-page: 74 year: 2022 ident: 5002_CR4 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2022.06.017 – volume: 10 start-page: 1570 issue: 3 year: 2023 ident: 5002_CR9 publication-title: ESC Heart Fail doi: 10.1002/ehf2.14272 – ident: 5002_CR1 doi: 10.1016/j.jacc.2024.11.030 – volume: 72 start-page: 1898 issue: 16 year: 2018 ident: 5002_CR25 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.07.080 – volume: 52 start-page: 403 issue: 3 year: 2018 ident: 5002_CR28 publication-title: J INTERV CARD ELECTR – volume: 76 start-page: 3022 issue: 25 year: 2020 ident: 5002_CR11 publication-title: J AM COLL CARDIOL doi: 10.1016/j.jacc.2020.08.044 – volume: 58 start-page: 2501 issue: 24 year: 2011 ident: 5002_CR21 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2011.09.020 – volume: 9 year: 2022 ident: 5002_CR26 publication-title: Front Surg – volume: 93 start-page: 171 issue: 2 year: 2004 ident: 5002_CR29 publication-title: AM J CARDIOL doi: 10.1016/j.amjcard.2003.09.034 – volume: 80 start-page: 46 year: 2023 ident: 5002_CR6 publication-title: Prog Cardiovasc Dis doi: 10.1016/j.pcad.2023.08.003 – volume: 112 start-page: 855 issue: 6 year: 2005 ident: 5002_CR24 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.104.507723 – volume: 8 year: 2021 ident: 5002_CR5 publication-title: Front Cardiovasc Med – volume: 118 start-page: 861 issue: 5 year: 2022 ident: 5002_CR14 publication-title: Arq Bras Cardiol – volume: 9 issue: 12 year: 2021 ident: 5002_CR16 publication-title: Ann Transl Med doi: 10.21037/atm-21-2783 – volume: 68 start-page: 618 issue: 5 year: 2016 ident: 5002_CR17 publication-title: Indian Heart J doi: 10.1016/j.ihj.2016.02.007 – volume: 64 start-page: 53 issue: 1 year: 2022 ident: 5002_CR22 publication-title: Cor Vasa doi: 10.33678/cor.2021.124 – volume: 45 start-page: 5084 issue: 47 year: 2024 ident: 5002_CR2 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehae710 – volume: 18 start-page: 113 issue: 1 year: 2015 ident: 5002_CR19 publication-title: Europace doi: 10.1093/europace/euv302 – volume: 54 start-page: 220 issue: 3 year: 2009 ident: 5002_CR23 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2009.05.006 – volume: 3 start-page: 896 issue: 11 year: 2015 ident: 5002_CR27 publication-title: JACC-HEART FAIL doi: 10.1016/j.jchf.2015.06.011 – volume: 70 start-page: 65 year: 2023 ident: 5002_CR3 publication-title: HELL J CARDIOL – volume: 43 start-page: 450 issue: 5 year: 2020 ident: 5002_CR7 publication-title: Clin Cardiol doi: 10.1002/clc.23341 – volume: 102 start-page: 3549 issue: 44 year: 2022 ident: 5002_CR13 publication-title: Zhonghua Yi Xue Za Zhi – volume: 13 start-page: 1885 issue: 9 year: 2016 ident: 5002_CR18 publication-title: HEART RHYTHM doi: 10.1016/j.hrthm.2016.04.018 |
| SSID | ssj0017809 |
| Score | 2.3849196 |
| Snippet | Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to... Objective Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We... ObjectivePercutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We... Abstract Objective Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 564 |
| SubjectTerms | Ablation Ablation (Surgery) Adult Aged Arrhythmia Beta blockers Cardiac arrhythmia Cardiac patients Cardiomyopathy Cardiomyopathy, Hypertrophic Cardiomyopathy, Hypertrophic - diagnostic imaging Cardiomyopathy, Hypertrophic - physiopathology Cardiomyopathy, Hypertrophic - surgery Cardiovascular magnetic resonance imaging Care and treatment Catheter Ablation - adverse effects Catheter Ablation - methods Catheters Echocardiography Edema Electrophysiologic Techniques, Cardiac Fainting Female Heart Heart diseases Heart function Humans Hypertrophic obstructive cardiomyopathy Magnetic resonance imaging Male Methods Middle Aged Pacemakers Patient outcomes Patients Radiofrequency ablation Recovery of Function Septal radiofrequency ablation Software Statistical analysis Tamponade Time Factors Treatment Outcome Veins & arteries Ventricle Ventricular Function, Left Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfJt1lRYEDxI2Sb-qj6u4LMKKBxf21vSTGdBkyKzC_HurO5lhggcvXtOdSdL1-mq6-itC3kUQyTPnax90wAQFdK2bZOtWMRkcT7Ypp9Kuv8qrG_7lVtwetfrKNWETPfC0cOeYI3SOC-1A4q0u4xmIrZOgHQNoU_a-GPP2ydS8f6Cg0fsjMiDPt-iFVVfn1q2NKO08FmGosPX_7ZOPgtKyYPIoAl0-Ig9n6Egvpld-TO7F_gm5fz1vjj8lm29x9L8Q7EXM5mnsA4apLP4fdBs3iLHpaMN6SONUPL2j1k11cHTd05ledUvz_7J0hcnpeDcOm9Xa08HNHLO_Iy0_OPzcDbmR8e4Zubn8_P3TVT03VKg9Z11bg2fCetV5sFx3LjEEd8nFZEXUIVklRIzAGq208yzoJLkILiJosaqxoBV7Tk76oY8vCc27mRyTq6AF59FbLTxmRoBgQbLIVVORD_v1NZuJN8OUfAOkmaRhUBqmSMO0FfmYRXCYmTmvywXUBDNrgvmXJlTkfRagyZaJUvJ2PmCAL5w5rswFiEKg1uHjzhYz0aL8cnivAma26K3BtZJad9DKirw9DOc7c5VakWyeI9ChKQYVeTFpzOGTMHFGdweqIrDQpcU3L0f69arwfSO4QJCnmtP_sUqvyIOu2AGgOZyRE9Sg-Bpx1Z17U0zoD5TSIGc priority: 102 providerName: Directory of Open Access Journals |
| Title | Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40753187 https://www.proquest.com/docview/3236992816 https://www.proquest.com/docview/3235963738 https://pubmed.ncbi.nlm.nih.gov/PMC12317570 https://doaj.org/article/0262b459b86b4fb99918e1b689b3881f |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swEBZbC2MvY7_nrSsaDPYwTG3Lkk5PoxktZdBSygphL0KS5SXQ2ZnTDfLf7yQrWc1gL3mwZMfyfXf6TjrdEfLeA28dsy53jWrQQQGVq6I1eSmZaGzdmiKeSju_EGfX9Zc5n6cFt3UKq9zaxGiom96FNfIjVjGhVAWl-LT6mYeqUWF3NZXQuE_2Q-qygGo53zlcpYRCbQ_KgDhaoy2WVR4KuBY8FvWYTEYxZ_-_lvnO1DQNm7wzD50-Jo8SgaTHo8SfkHu-e0oenKct8mdkdekH9wspn0efnvoORxZBcEPXfoVMmw6mWfbtMIZQb6ixYzQcXXY0JVld07A6Sxfoog63Q79aLB3tbco0-9vT-MD-x6YP5Yw3z8n16cnXz2d5KquQu5pVZQ6OceNk5cDUqrItftmytb413KumNZJz74EVSirrWKNaUfPGeqQuRhYGlGQvyF7Xd_4VoWFPs0YXq1G8rr0zijv0jwApg2C-lkVGPm6_r16N2TN09DpA6FEaGqWhozR0mZFZEMGuZ8h8HS_0w3edFAn7i8rWXFkQCCUb-C340gpQlgGUbUY-BAHqoJ8oJWfSMQN84ZDpSh8Dj2nUKvy7g0lP1Cs3bd5CQCe9Xuu_KMzIu11zuDPEqkXJhj4czZpkkJGXI2J2Q0L3GY0eyIzABEuTMU9buuUiZv1GioFUTxav__9eb8jDKiIcEOgHZA-x4d8ib7q1h1E5Dsn-7OTi8uowrj7g79Xs2x_TvBxt |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJFAHFDUxI5j-4BQeVRb2q04tNLejO047EqQhKQF7Z_iNzJ2kqURErdeY8dJPJ9n5ovHMwi9cIKVlhob20IWQFCEjGVS6jjlNC9MVuoknEqbH-ez0-zTgi220O_xLIwPqxx1YlDURW39P_JdSmguJRFp_rb5EfuqUX53dSyh0cPi0K1_AWXr3hx8APm-JGT_48n7WTxUFYhtRkkaC0uZtpxYoTNJTAkDp6VxpWZOFqXmjDknaCK5NJYWsswzVhgHllvzRAvJKYx7BV0Fw5t4sscXG4KXcpHI8WCOyHc70P2cxL5gbMJCEZGJ8Qs1Av61BBdM4TRM84Ld27-Fbg4OK97rEXYbbbnqDro2H7bk76Lms2vtObiYrj7vsKtgJgPovuHONeDZ41YXq7ps-5DtNdamj77DqwoPSV077P8G4yVQ4vasrZvlyuLaDJltfzocBqy_r2tfPnl9D51eyoTfR9tVXbmHCPs91AwoXSFZljmrJbPAxwS4KDl1GU8i9HqcX9X02TpUYDkiV700FEhDBWmoNELvvAg2PX2m7XChbr-qYeFC_5yYjEkjcoCu8f60cKnJhTRUiLSM0CsvQOX1AUjJ6uFYA7ywz6yl9gQLadsIPG5n0hPWsZ02jxBQgx7p1F_UR-j5ptnf6WPjgmR9HwZqlFMRoQc9YjafBHQdlKzgERITLE2-edpSrZYhyzi4NOBa8uTR_9_rGbo-O5kfqaOD48PH6AYJaBcA-h20DThxT8BnOzNPw0LB6Mtlr8w_L6FWMg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Percutaneous+endocardial+septal+radiofrequency+ablation+in+patients+with+hypertrophic+obstructive+cardiomyopathy&rft.jtitle=BMC+cardiovascular+disorders&rft.au=Tian%2C+Aiju&rft.au=Cheng%2C+Yunjiu&rft.au=Jia%2C+Yuhe&rft.au=Zhang%2C+Tianjing&rft.date=2025-08-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2261&rft.eissn=1471-2261&rft.volume=25&rft.issue=1&rft_id=info:doi/10.1186%2Fs12872-025-05002-1&rft.externalDocID=A850260121 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2261&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2261&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2261&client=summon |